Find the latest Pediatric Dermatology news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Find the latest Pediatric Dermatology news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.

The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy or active…

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease